Advertisement

Reboxetine prevents the tranylcypromine-induced increase in tyramine levels in rat heart

  • P. Dostert
  • M. G. Castelli
  • P. Cicioni
  • M. Strolin Benedetti
Conference paper
Part of the Journal of Neural Transmission book series (NEURAL SUPPL, volume 41)

Summary

This study aimed to examine whether the increase in heart radioactivity levels after intravenous injection of 14C-tyramine to rats pretreated with the irreversible MAO inhibitor tranylcypromine could be antagonized by reboxetine, a potent and selective noradrenaline uptake blocker.

Keywords

Monoamine Oxidase Inhibitor Uptake Blocker Central Noradrenergic System Cheese Effect Tyramine Hydrochloride 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Bieck PR, Antonin KH (1989) Tyramine potentiation during treatment with MAO inhibitors: brofaromine and moclobemide vs irreversible inhibitors. J Neural Transm [Suppl] 28: 21–31.Google Scholar
  2. Cocchiara G, Battaglia R, Pevarello P, Strolin Benedetti M (1991) Comparison of the disposition and of the metabolic pattern of reboxetine, a new antidepressant, in the rat, dog, monkey and man. Eur J Drug Metab Pharmacokinet 16: 231–239.PubMedCrossRefGoogle Scholar
  3. Dollery CT, Brown MJ, Davies DS, Strolin Benedetti M (1984) Pressor amines and monoamine oxidase inhibitors. In: Tipton KF, Dostert P, Strolin Benedetti M (eds) Monoamine oxidase and disease. Prospects for therapy with reversible inhibitors. Academic Press, London, pp 429–441.Google Scholar
  4. Dostert P (1984) Myth and reality of the classical MAO inhibitors. Reasons for seeking a new generation. In: Tipton KF, Dostert P, Strolin Benedetti M (eds) Monoamine oxidase and disease. Prospects for therapy with reversible inhibitors. Academic Press, London, pp 9–24.Google Scholar
  5. Dostert P, Strolin Benedetti M, Sontag N (1981) Some biochemical aspects of the potential benefit of associating MD 780515 with tricyclic antidepressants. J Pharm Pharmacol 33: 639–643.PubMedCrossRefGoogle Scholar
  6. Hendley ED, Snyder SH (1968) Relationship between the action of monoamine oxidase inhibitors on the noradrenaline uptake system and their antidepressant efficacy. Nature 220: 1330–1331.PubMedCrossRefGoogle Scholar
  7. Kan JP, Strolin Benedetti M (1981) Characteristics of the inhibition of rat brain monoamine oxidase in vitro by MD 780515. J Neurochem 36: 1561–1571.PubMedCrossRefGoogle Scholar
  8. Korn A, Da Prada M, Raffesberg W, Allen S, Gasic S (1988) Tyramine pressor effect in man: studies with moclobemide, a novel, reversible monoamine oxidase inhibitor. J Neural Transm [Suppl] 26: 57–71.Google Scholar
  9. Melloni P, Carniel G, Della Torre A, Bonsignori A, Buonamici M, Pozzi O, Ricciardi S, Rossi AC (1984) Potential antidepressant agents. a-Aryloxy-benzyl derivatives of ethanolamine and morpholine. Eur J Med Chem 19: 235–242.Google Scholar
  10. Pare CMB, Hallstrom C, Kline N, Cooper TB (1982) Will amitriptyline prevent the “cheese” reaction of monoamine oxidase inhibitors? Lancet ii: 183–186.CrossRefGoogle Scholar
  11. Richelson E, Pfenning M (1984) Blockade by antidepressants and related compounds of biogenic amine uptake into rat brain synaptosomes: most antidepressants selectively block norepinephrine uptake. Eur J Pharmacol 104: 277–286.PubMedCrossRefGoogle Scholar
  12. Riva M, Brunello N, Rovescalli AC, Galimberti R, Carfagna N, Carminati P, Pozzi O, Ricciardi S, Roncucci R, Rossi A, Racagni G (1989) Effect of reboxetine, a new antidepressant drug, on the central noradrenergic system: behavioural and biochemical studies. J Drug Dev 1: 243–253.Google Scholar
  13. Strolin Benedetti M, Dosiert P, Guffroy C, Tipton KF (1983) Partial or total protection from long-lasting monoamine oxidase inhibitors (MAOIs) by new short-acting MAOIs of type A MD 780515 and type B MD 780236. Mod Probi Pharmaco-psychiatry 19: 82–104.Google Scholar

Copyright information

© Springer-Verlag 1994

Authors and Affiliations

  • P. Dostert
    • 1
  • M. G. Castelli
    • 1
  • P. Cicioni
    • 1
  • M. Strolin Benedetti
    • 1
  1. 1.Farmitalia Carlo ErbaResearch and Development — Erbamont GroupMilanItaly

Personalised recommendations